AGA
SURF

Altrinsic Global Advisors’s Surface Oncology, Inc. Common Stock SURF Stock Holding History

Altrinsic Global Advisors’s Portfolio SURF Stock Details SURF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-160,078
Closed -$679K – 84
2018
Q4 		$679K Buy
160,078
+10,078
+7% +$77.8K 0.03% 75
2018
Q3 		$1.64M Buy
150,000
+109,601
+271% +$1.28M 0.07% 66
2018
Q2 		$659K Buy
+40,399
New +$585K 0.03% 78

Other funds holding SURF

AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Altrinsic Global Advisors's SURF Position: Q1 2019 in Review

Altrinsic Global Advisors sold out of Surface Oncology, Inc. Common Stock (SURF) in Q1 2019, closing a stake of 160,078 shares — an estimated $679K sold.

Altrinsic Global Advisors first reported a position in SURF in Q2 2018 and held it in 3 quarters. The position peaked at $1.64M in Q3 2018. 54 funds tracked by Wall St. Rank hold SURF as of Q1 2019.

  • Altrinsic Global Advisors reported no remaining Surface Oncology, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Altrinsic Global Advisors sold 160,078 Surface Oncology, Inc. Common Stock shares in Q1 2019, an estimated $679K.
  • Altrinsic Global Advisors first reported a position in Surface Oncology, Inc. Common Stock in Q2 2018 and held it in 3 quarters.
  • Altrinsic Global Advisors's Surface Oncology, Inc. Common Stock position peaked at $1.64M in Q3 2018.
  • 54 funds tracked by Wall St. Rank held Surface Oncology, Inc. Common Stock as of Q1 2019.

Based on Altrinsic Global Advisors's 13F filing for Q1 2019, filed 14 May 2019.